GOG263: RANDOMIZED CLINICAL TRIAL OF ADJUVANT RADIATION VERSUS CHEMORADIATION IN INTERMEDIATE RISK, STAGE I/IIA CERVICAL CANCER TREATED WITH INITIAL RADICAL HYSTERECTOMY AND PELVIC LYMPHADENECTOMY

Trial setting: Post radical hysterctomy cervical cancer, Intermediate risk, Stage I/IIA
Study Design: Adjuvant RT vs CRT

Sponsor(s): NCI-NRG

Planned No. of patients: 360

Current accrual: 280

Revision:
Update (11/2017): Based on the observed accrual rate through November 2017, power analysis and sample size calculations using the Gompertz model suggest that enrolling at least 342 eligible and evaluable patients will result in the required number of recurrences without any changes to the study operating characteristics.
Assuming uniform accrual with 5% ineligible proportion estimated from this study, the targeted accrual is 360 patients expected to be met in 2020.

GOG263: RANDOMIZED CLINICAL TRIAL OF ADJUVANT RADIATION VERSUS CHEMORADIATION IN INTERMEDIATE RISK, STAGE I/IIA CERVICAL CANCER TREATED WITH INITIAL RADICAL HYSTERECTOMY AND PELVIC LYMPHADENECTOMY



GOG263: RANDOMIZED CLINICAL TRIAL OF ADJUVANT RADIATION VERSUS CHEMORADIATION IN INTERMEDIATE RISK, STAGE I/IIA CERVICAL CANCER TREATED WITH INITIAL RADICAL HYSTERECTOMY AND PELVIC LYMPHADENECTOMY